-
Something wrong with this record ?
Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors
V. Pejchal, Š. Štěpánková, M. Pejchalová, K. Královec, R. Havelek, Z. Růžičková, H. Ajani, R. Lo, M. Lepšík,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acetylcholinesterase metabolism MeSH
- Benzothiazoles chemical synthesis chemistry pharmacology MeSH
- Butyrylcholinesterase metabolism MeSH
- Cholinesterase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Hydrophobic and Hydrophilic Interactions MeSH
- Jurkat Cells MeSH
- Carbamates chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Molecular Structure MeSH
- Cell Line, Tumor MeSH
- Cell Proliferation drug effects MeSH
- Molecular Docking Simulation * MeSH
- Cell Survival drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
In the current study, sixteen novel derivatives of (R)-1-(6-fluorobenzo[d]thiazol-2-yl)ethanamine were synthesized as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. Chemical structures together with purity of the synthesized compounds were substantiated by IR, (1)H, (13)C, (19)F NMR, high resolution mass spectrometry and elemental analysis. The optical activities were confirmed by optical rotation measurements. The synthesized compounds were evaluated for their AChE and BChE inhibitory activities. In addition, the cytotoxicity of the most active compounds was investigated against human cell lines employing XTT tetrazolium salt reduction assay and xCELLigence system allowing a label-free assessment of the cells proliferation. Our results demonstrated that the inhibitory mechanism was confirmed to be pseudo-irreversible, in line with previous studies on carbamates. Compounds indicated as 3b, 3d, 3l and 3n showed the best AChE inhibitory activity of all the evaluated compounds and were up to tenfold more potent than standard drug rivastigmine. The binding mode was determined using state-of-the-art covalent docking and scoring methodology. The obtained data clearly demonstrated that 3b, 3d, 3l and 3n benzothiazole carbamates possess high inhibitory activity against AChE and BChE and concurrently negligible cytotoxicity. In conclusion, our results indicate, that these derivatives could be promising in an effective therapeutic intervention for Alzheimer's disease.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000368
- 003
- CZ-PrNML
- 005
- 20170113113629.0
- 007
- ta
- 008
- 170103s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bmc.2016.02.033 $2 doi
- 024 7_
- $a 10.1016/j.bmc.2016.02.033 $2 doi
- 035 __
- $a (PubMed)26947959
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pejchal, Vladimír $u Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic. Electronic address: vladimir.pejchal@upce.cz.
- 245 10
- $a Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors / $c V. Pejchal, Š. Štěpánková, M. Pejchalová, K. Královec, R. Havelek, Z. Růžičková, H. Ajani, R. Lo, M. Lepšík,
- 520 9_
- $a In the current study, sixteen novel derivatives of (R)-1-(6-fluorobenzo[d]thiazol-2-yl)ethanamine were synthesized as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. Chemical structures together with purity of the synthesized compounds were substantiated by IR, (1)H, (13)C, (19)F NMR, high resolution mass spectrometry and elemental analysis. The optical activities were confirmed by optical rotation measurements. The synthesized compounds were evaluated for their AChE and BChE inhibitory activities. In addition, the cytotoxicity of the most active compounds was investigated against human cell lines employing XTT tetrazolium salt reduction assay and xCELLigence system allowing a label-free assessment of the cells proliferation. Our results demonstrated that the inhibitory mechanism was confirmed to be pseudo-irreversible, in line with previous studies on carbamates. Compounds indicated as 3b, 3d, 3l and 3n showed the best AChE inhibitory activity of all the evaluated compounds and were up to tenfold more potent than standard drug rivastigmine. The binding mode was determined using state-of-the-art covalent docking and scoring methodology. The obtained data clearly demonstrated that 3b, 3d, 3l and 3n benzothiazole carbamates possess high inhibitory activity against AChE and BChE and concurrently negligible cytotoxicity. In conclusion, our results indicate, that these derivatives could be promising in an effective therapeutic intervention for Alzheimer's disease.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a benzothiazoly $x chemická syntéza $x chemie $x farmakologie $7 D052160
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a karbamáty $x chemická syntéza $x chemie $x farmakologie $7 D002219
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a Jurkat buňky $7 D019169
- 650 12
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, Pardubice 532 10, Czech Republic.
- 700 1_
- $a Pejchalová, Marcela $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, Pardubice 532 10, Czech Republic.
- 700 1_
- $a Královec, Karel $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, Pardubice 532 10, Czech Republic.
- 700 1_
- $a Havelek, Radim $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, Pardubice 532 10, Czech Republic.
- 700 1_
- $a Růžičková, Zdeňka $u Department of General and Inorganic Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic.
- 700 1_
- $a Ajani, Haresh $u Institute of Organic Chemistry and Biochemistry v.v.i and Gilead Sciences and IOCB Research Center, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic; Regional Center of Advanced Technologies and Materials, Department of Physical Chemistry, Palacký University, Olomouc, 771 46 Olomouc, Czech Republic. $7 gn_A_00002766
- 700 1_
- $a Lo, Rabindranath $u Institute of Organic Chemistry and Biochemistry v.v.i and Gilead Sciences and IOCB Research Center, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Lepšík, Martin $u Institute of Organic Chemistry and Biochemistry v.v.i and Gilead Sciences and IOCB Research Center, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic.
- 773 0_
- $w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 24, č. 7 (2016), s. 1560-72
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26947959 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170113113730 $b ABA008
- 999 __
- $a ok $b bmc $g 1179508 $s 960935
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 24 $c 7 $d 1560-72 $e 20160226 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769
- LZP __
- $a Pubmed-20170103